SII to produce nearly 30,000 doses of experimental Ebola vaccine for use in Uganda outbreak
- The latest Ebola outbreak has claimed the lives of 19 people among 58 cases that were recorded currently. However, chances are that the number of death and cases are probably higher as per reports.
Indian biotechnology and biopharmaceuticals company, Serum Institute of India is planning to manufacture about 20,000 to 30,000 doses of an experimental Ebola vaccine for use in trials against the latest outbreak in Uganda. The experimental vaccines are expected to be delivered by next month's end. Currently, Ugandan President Yoweri Museveni has imposed a lockdown in two districts due to the Ebola outbreak.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more